A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

Completed · Phase 2 · Has a placebo group

Conditions studied: Hypertrophic Scar

In brief

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.

Key facts

Study ID

NCT02030275

Run by

RXi Pharmaceuticals, Corp.

People needed

25

Starts

2013-11-01

Expected to finish

2016-06-01

Last updated by the study team

2016-06-21

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults, 21-55 years of age in general good health
• Previous partial hysterectomy, Cesarean section or abdominoplasty surgery resulting in a transverse hypertrophic scar of ≥ 11 cm in length
• Scar to be revised must have been present for > 9 months

You may not qualify if…

• Use of tobacco or nicotine-containing products
• Pregnant or lactating
• Post-menopausal or full hysterectomy

Where it is running

• Study site — Lake Worth, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — St Louis, Missouri, United States
• Study site — Huntersville, North Carolina, United States
• Study site — San Pedro Sula, Honduras

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.